TruWay Health Advances FUSION-72 Study to Investigate Multimodal Digital Biomarkers for Acute Deterioration

News & Insights | September 1, 2026

TruWay Health is advancing FUSION-72: Multimodal Digital Biomarker Prediction of Acute Deterioration, a research initiative conducted under TH-FUSION72-2026-001.

The study is focused on an emerging area of clinical research: understanding whether combinations of digital biomarkers and longitudinal clinical signals can help identify patterns associated with acute deterioration before clinically significant events become apparent.

Moving Beyond Single-Parameter Monitoring

FUSION-72 is designed around a multimodal research framework that examines relationships among multiple streams of clinical and digital information rather than relying on a single measurement.

Areas of investigation include:

• Multimodal digital biomarker integration
• Temporal changes in patient status
• Longitudinal clinical trajectories
• Early-warning signal detection
• Biomarker concordance and discordance
• Data provenance and quality
• Remote clinical surveillance
• Predictive-model development and evaluation
• Clinically meaningful changes preceding deterioration

By studying these relationships together, the research seeks to better characterize how complex clinical states evolve over time.

A New Architecture for Clinical Surveillance

The FUSION-72 research framework also reflects TruWay Health's interest in integrating clinical research, artificial intelligence, digital health infrastructure, and secure data governance.

The conceptual research pipeline is:

Clinical Data → Secure Processing → Digital Biomarker Extraction → Multimodal Fusion → Temporal Analysis → Predictive Modeling → Clinical Evaluation → Auditable Research Record

The infrastructure is designed so that sensitive clinical information can remain within appropriately governed systems while cryptographic technologies can be used where appropriate for provenance, authorization, event integrity, and auditability.

Principal Investigator Perspective

“FUSION-72 is fundamentally about changing the way we think about clinical deterioration—from recognizing an event after it happens to studying the complex digital signals that may precede it. Our objective is to build a scientifically rigorous framework for understanding multimodal biomarkers while maintaining patient privacy, data integrity, and meaningful clinical oversight.”

— Gavin Solomon, Principal Investigator, TruWay Health

The quotation above is drafted for publication based on the study's stated research direction and should be reviewed and approved by Gavin Solomon before publication as a direct quotation.

Central Clock Management and Research Provenance

A central component of the proposed technical architecture is Central Clock Management.

Accurate temporal sequencing is essential when studying deterioration. The research infrastructure can establish consistent timestamps for data acquisition, biomarker generation, analytical processing, model execution, investigator actions, and research-record finalization.

This creates an auditable temporal framework supporting:

Time Synchronization → Event Sequencing → Provenance → Verification → Audit

Where blockchain or EVM infrastructure is used, the ledger is intended as an integrity and verification layer, not as a repository for protected health information.

Toward More Connected Clinical Research

FUSION-72 represents TruWay Health's continuing interest in developing research infrastructure that connects multimodal clinical data, digital biomarkers, artificial intelligence, secure computing, and longitudinal surveillance.

The long-term scientific objective is to determine whether multimodal digital signals can provide reproducible information about evolving patient risk and whether those signals can ultimately support better research methodologies for early recognition of clinical deterioration.

Study: FUSION-72: Multimodal Digital Biomarker Prediction of Acute Deterioration
Protocol: TH-FUSION72-2026-001
Principal Investigator: Gavin Solomon
Organization: TruWay Health, Inc.
Status: Released
Date: September 1, 2026

TruWay Health's stated vision emphasizes combining healthcare innovation, advanced technologies, operational excellence, and connected healthcare ecosystems.

Important: FUSION-72 is a research initiative. Any predictive model or digital biomarker identified through the study requires appropriate validation and clinical governance before being used to guide patient care.